ライフサイエンスコーパス: escalation

1 ffecting this planning (e.g., regarding dose escalation).

2 golimod because of safety reasons or therapy escalation.

3 targeting agents and radiation therapy dose escalation.

4 topotecan in 3-week cycles using 3 + 3 dose escalation.

5 naptic plasticity associated with aggression escalation.

6 and 22 were eligible and evaluable for dose escalation.

7 ) sessions until LgA rats displayed a robust escalation.

8 Receipt of treatment and treatment escalation.

9 h could be restored with further Notch1 dose escalation.

10 g solubilization, biocompatibility, and dose escalation.

11 obesity was not associated with treatment or escalation.

12 H counteract opioid analgesia and drive dose escalation.

13 onsistently lower magnitude than the current escalation.

14 d durvalumab doublets in parallel 3 + 3 dose escalations.

15 tal reports, daily symptom diaries, and dose escalations.

16 ma were reported for protocols with <6 doses escalation (2.6% [1.1%-4.1%] versus 2.6% [1.9%-3.2%]).

17 Dose escalation (3 + 3 design) in all solid tumors was follow

18 sly treated AL were enrolled, 15 during dose escalation (6 at 2 mg, 3 at 3 mg, and 6 at 4 mg) and 12

19 seven patients were enrolled: 11 during dose escalation (6 at 4.0 mg and 5 at 5.5 mg) and 16 during d

20 The data dimensionality escalation accentuates limitations, inherent to manual a

21 Antimicrobial de-escalation (ADE) is a strategy to reduce the spectrum of

22 y at trial entry according to the 3 + 3 dose-escalation algorithm and depending on the number of dose

23 itching to nilotinib than with imatinib dose escalation, although the difference was not statisticall

24 Results In the dose-escalation and -expansion cohorts, 33 and 18 patients, r

25 atal neuroadaptations, resulting in drinking escalation and addiction phenotypes.

26 RIPF remains a major limiting factor to dose escalation and an obstacle to applying more promising ne

27 of axillary management, and any policy of de-escalation and avoidance of morbidity must not compromis

28 PPI dose escalation and continued chronic therapy in those unresp

29 These findings have to be confirmed in escalation and deescalation procedures based on early i-

30 defences in Ficus can be driven towards both escalation and divergence in individual traits, in combi

31 Phase 1 study with dose escalation and dose expansion at the University of Texas

32 The study was done in two parts, with dose-escalation and dose-expansion phases.

33 Results Data in 132 patients from the escalation and expansion arms are reported (May 15, 2015

34 Results The dose-escalation and expansion phases enrolled 26 and 25 patie

35 sed or refractory AML, from the phase 1 dose-escalation and expansion phases of the study.

36 e recommended dose of 750 mg/day in the dose-escalation and expansion phases.

37 This first-in-human, dose-escalation and expansion study evaluated the safety, pha

38 phase 1/2, open-label, non-comparative, dose escalation and expansion trial (CheckMate 040) of nivolu

39 Escalation and information transfer skills are not curre

40 he proportion of patients who lost MMR on de-escalation and regained MMR on TKI resumption.

41 at target doses from 200 to 1,200 mg in dose-escalation and safety expansion cohorts.

42 itioner engagement, the need for reaction to escalation and the need for clinical judgment, and the i

43 g patients who are candidates for therapy de-escalation), and not in Group 3 or SHH.

44 Smoking initiation and escalation are affected differentially by ADHD subtype a

45 Reasons for this escalation are unclear and identifying these remains a p

46 Studies of more ambitious de-escalation are warranted.

47 aimed to examine the effects of treatment de-escalation as a prelude to complete cessation, not only

48 ed drug abstinence, LgA rats returned to pre-escalation baseline levels of responding for sufentanil

49 Among cases with antibiotic treatment escalation by day 2, 90% (37/41) had nonresponse at day

50 lution after a species jump has been further escalation by the virus in the face of widespread host r

51 Predictors of treatment escalation by week 12 in patients initially treated with

52 Dose escalation ceased at 160 mg per day given lack of MTD an

53 ublication of a first-in-man phase I/II dose escalation clinical trial in patients with radiation-ind

54 f three patients enrolled in the 450 mg dose-escalation cohort had two dose-limiting toxicities (grad

55 In this phase I, open-label, dose-escalation, cohort-expansion study, patients with relaps

56 rmany; 27 patients were enrolled in the dose-escalation cohorts (0.125-1.75 mg/kg) and 31 patients in

57 of 66 patients were enrolled (54 in the dose-escalation cohorts and 12 in the safety expansion).

58 s given at 300, 600, 900, or 1200 mg in dose-escalation cohorts and 1200 mg in the safety expansion.

59 ose ramp-up period for most patients in dose-escalation cohorts and for all patients in safety expans

60 Sixty-six patients were enrolled (30, dose-escalation cohorts; 36, safety expansion).

61 urthermore, the feasibility of triazole dose escalation, combination therapy, and prophylaxis were ex

62 atients were enrolled in seven cohorts (dose-escalation component).

63 t 1, patients received eltrombopag, and dose-escalation criteria for part 2 were determined.

64 Finally, in vitro dose-escalation cytotoxicity assays confirm the biocompatibil

65 After a 2-week lead-in with weekly dose escalation, daily venetoclax was given at 300, 600, 900,

66 Methods In a 3 + 3 dose-escalation design (n = 25), patients received a single d

67 orally administered in a standard 3 + 3 dose-escalation design at four different dosing schedules, to

68 ed or RRMM patients into an open-label, dose-escalation design to determine the maximum tolerated dos

69 We used a rolling six escalation design to determine the maximum tolerated dos

70 patients were assigned following a 3+3 dose-escalation design to one of four cohorts to receive one

71 f 100 to 1,800 mg, according to a 3 + 3 dose-escalation design, followed by an expansion phase at the

72 0 mg twice daily in a standard 3 + 3 dose de-escalation design.

73 g an open-label, single-ascending 3 + 3 dose-escalation design.

74 10 and taking only mesalazine, and treatment escalation during the 12 study weeks to anti-tumour necr

75 Part 1 (dose escalation) evaluated 4 daratumumab doses plus lenalidom

76 ognitive performance, and suppressed seizure escalation, even when therapy was initiated 36 hours aft

77 e report interim data from a phase I/II dose-escalation/expansion study of NEOD001 in patients with A

78 (slow escalation; n = 70), 40-mg 2-week dose escalation (fast escalation, n = 70), oral placebo (n =

79 Phase 1/2a, multicenter, open-label, dose-escalation, fellow-eye-controlled study.

80 weighting revealed lower rates of antibiotic escalation for oral vs intravenous therapy (odds ratio [

81 y of switching to nilotinib vs imatinib dose escalation for patients with suboptimal cytogenetic resp

82 It also has the potential to enable early de-escalation from broad-spectrum empirical antimicrobials

83 osuppression (if possible): ganciclovir dose escalation, ganciclovir and foscarnet combination, and a

84 During dose escalation, grade 2 dose-limiting toxic effects occurred

85 phase group (n=33) with those in the dose de-escalation group that received PF-04136309 at the recomm

86 patients received veliparib (22 in the dose-escalation group; ten in the safety expansion group); 31

87 This trend for de-escalation has accompanied a shift in understanding of h

88 Radiotherapy de-escalation has the potential to improve the therapeutic

89 The escalation hypothesis posits that predation by increasin

90 Upon subsequent re-escalation (ie, after the return to extended access to s

91 y, or equivalent placebo with mandatory dose escalation if no serious adverse effects were experience

92 heter ablation than among those receiving an escalation in antiarrhythmic drug therapy.

93 rtunities and energy policies have led to an escalation in biofuel consumption at the expenses of foo

94 Such activation might cause a sharp escalation in depolarizing current and underlie the stee

95 ibute to the dysregulation of NAc DA and the escalation in ethanol intake associated with SI.

96 s the resulting theoretical definition of de-escalation in healthcare is "a collective term for a ran

97 fronto-parietal functional network, while an escalation in MaxDrinks was associated with a greater di

98 cular testing had the potential to enable de-escalation in number and/or spectrum of antimicrobials i

99 e reactions were markedly reduced during OIT escalation in omalizumab-treated subjects for percentage

100 ut not C57BL/6J mice showed rapid and robust escalation in palatable food consumption.

101 This study evaluated the effects of RT dose escalation in the treatment of IHCC.

102 overnment should consider as a result of the escalation in violence and more support for conciliatory

103 alcohol use disorders, and an increase, or 'escalation', in MaxDrinks may be indicative of greater r

104 ose-limiting toxicities observed during dose escalation included grade 3 increased alanine aminotrans

105 urport to use, the antecedents that their de-escalation intervention is targeting, its key attributes

106 INTERPRETATION: TKI de-escalation is safe for most patients with excellent resp

107 robust evidence-base for the efficacy of de-escalation is striking and must, at least in part, be cr

108 De-escalation is the recommended first-line response to pot

109 d after the second hospital day), antibiotic escalation, length of stay (LOS), and cost.

110 Escalation (macroevolutionary increase) or divergence (d

111 nt in rats given extended access to cocaine: escalation, motivation, self-imposed abstinence in the f

112 gilteritinib once daily in one of seven dose-escalation (n=23) or dose-expansion (n=229) cohorts.

113 n = 70), 40-mg 2-week dose escalation (fast escalation, n = 70), oral placebo (n = 71; double-blind)

114 n = 71), 40-mg 8-week dose escalation (slow escalation; n = 70), 40-mg 2-week dose escalation (fast

115 70), 40-mg 4-week dose escalation (standard escalation; n = 71), 40-mg 8-week dose escalation (slow

116 During dose escalation, nivolumab showed a manageable safety profile

117 lation than the control group (34%), with de-escalation occurring sooner in the BCID group (48 h; P =

118 st commonly reported environment in which de-escalation occurs, and nursing the disciplinary group mo

119 Experience-dependent escalation of aggression in female hamsters depends on a

120 Dose escalation of alisertib followed the rolling six design.

121 adverse event frequency did not change with escalation of allergen dose.

122 Escalation of attack therapy improves outcome.

123 This escalation of attack therapy significantly improved outc

124 ic review and meta-analysis of studies of de-escalation of BMAs, and two randomized trials of BMAs in

125 ing junior surgeons a systematic approach to escalation of care improved multiple core skills require

126 Prompt escalation of care in the setting of patient deteriorati

127 Escalation of care involves the recognition, communicati

128 ne whether an intervention could improve the escalation of care skills of junior surgeons.

129 ication of core skills needed for successful escalation of care through literature review and 33 semi

130 arios involving simulated patients requiring escalation of care.

131 spitalizations, prolonged hospital stay, and escalation of care.

132 To determine whether dose escalation of carmustine in combination with dual-dose O

133 nk costs, and cognitive dissonance result in escalation of commitment behavior in the surgical ICU se

134 MAIN Escalation of commitment behavior was observed with self

135 be factors that are thought to contribute to escalation of commitment behaviors.

136 t illustrates common ICU narratives in which escalation of commitment can occur.

137 Escalation of commitment is a business term that describ

138 Escalation of commitment may be a contributor to high he

139 Our objective was to determine if escalation of commitment occurs in healthcare settings,

140 Escalation of commitment occurs in the surgical ICU, res

141 nd gender were identified as contributors to escalation of commitment.

142 hange in antimicrobial prescriptions (ie, de-escalation of empirical antimicrobial therapy or commenc

143 STN HFS prevented the re-escalation of heroin intake after abstinence in rats wit

144 itch to nilotinib 400 mg twice per day or an escalation of imatinib dose to 600 mg once per day (bloc

145 6-h sessions/day, but did not demonstrate an escalation of intake with 6-h access.

146 e "symptoms of addiction." It did, including escalation of intake, sensitized motivation for drug, co

147 ight language and environment for the timely escalation of patient care.

148 Dose escalation of rifampicin achieves >90% Wolbachia depleti

149 However, NAC altered neither the escalation of SA nor the motivation for cocaine.

150 land and Wales to identify periods of sudden escalation of scarlet fever.

151 thesis as a previously unknown factor in the escalation of seizures and suggest that acute administra

152 we provide empirical evidence for a gradual escalation of self-serving dishonesty and reveal a neura

153 o the previous one predicts the magnitude of escalation of self-serving dishonesty on the next decisi

154 the risk side of the substance use equation: escalation of substance use.

155 Escalation of therapy based on interim PET in pediatric

156 utcomes for patients in the IR-GR group, and escalation of therapy with PEI did not significantly imp

157 ng an increased frequency of assessments and escalation of thromboprophylaxis.

158 Conclusion Dose escalation of varlilumab to 10 mg/kg was well tolerated

159 To clarify the concept of de-escalation of violence and aggression as described withi

160 aversion-mediated learning, show accelerated escalation of voluntary ethanol consumption.

161 ggest a mechanism for its role in modulating escalation of voluntary ethanol intake.

162 We conducted a phase 1, dose-escalation, open-label trial of cAd3-EBO.

163 In this dose-escalation, open-label, phase 1 study, we recruited pati

164 the 18 patients and was managed with dose de-escalation or discontinuation per standard of care.

165 atients were enrolled into one of seven dose-escalation or dose-expansion cohorts assigned to receive

166 We assigned patients to dose-escalation or expansion cohorts, ranging from 0.05 mg/kg

167 t's condition relative to their own prior to escalation or retreat.

168 rnative strategies such as radiotherapy dose escalation or surgery.

169 obacco smoking was associated with treatment escalation (OR, 1.4; 95% CI, 1.1-1.7) over time, whereas

170 apsed/refractory BCP-ALL in a phase I dosage-escalation part and a phase II part, using 6-week treatm

171 Patient recruitment to the dose-escalation part reported here is closed.

172 icity, and all patients enrolled in the dose-escalation part were assessed for the secondary endpoint

173 A 3+3 dose-escalation phase (15 patients) was followed by an expans

174 lumab 0.1-10 mg/kg every 2 weeks in the dose-escalation phase (3+3 design).

175 who received 500 mg twice a day in the dose-escalation phase (grade 3 acne [n=1] and intolerable gra

176 In the dose escalation phase (n = 31), duvelisib 8 to 100 mg twice d

177 In the initial dose-escalation phase 1 stage of the trial, patients received

178 We first performed a dose escalation phase 1 study to determine the recommended ph

179 This was an open-label, dose-escalation phase 1 trial done at two study sites in Japa

180 In this single-centre, open-label, dose-escalation phase 1 trial, we recruited adult patients (a

181 In this open-label, dose-escalation phase 1-2a study, we gave monthly intrathecal

182 tients with advanced solid tumours in a dose-escalation phase 1a trial.

183 12, 2016), three (10%) patients in the dose-escalation phase and 20 (53%) in the dose-expansion phas

184 tients were treated (48 patients in the dose-escalation phase and 214 in the dose-expansion phase).

185 were enrolled into the study, 29 to the dose-escalation phase and 38 to the dose-expansion phase.

186 7 or less (Child-Pugh A or B7) for the dose-escalation phase and 6 or less (Child-Pugh A) for the do

187 dpoints were safety and tolerability for the escalation phase and objective response rate (Response E

188 15, 102 patients were enrolled into the dose-escalation phase and received treatment.

189 s suggested mutual assessment during the pre-escalation phase but not during escalated aggression.

190 30 (63%) of 48 patients in the dose-escalation phase died (not determined to be related to n

191 A dose-escalation phase was conducted at seven hospitals or aca

192 A 3+3 dose-escalation phase was followed by 2 expansion cohorts (PI

193 The primary endpoint of the dose-escalation phase was safety.

194 In the dose-escalation phase, 25 patients with heavily pretreated MM

195 In the dose-escalation phase, an MTD was not reached at doses rangin

196 During the cell dose-escalation phase, an objective complete response was obs

197 and 12 to placebo) were enrolled in the dose-escalation phase, in which the 30 mug and 60 mug doses w

198 In the dose-escalation phase, patients received 3 to 80 mg/m(2) of s

199 In the dose-escalation phase, patients who had progressed after trea

200 sion phase and 15% (95% CI 6-28) in the dose-escalation phase.

201 ed; 42 received treatment in the formal dose-escalation phase.

202 dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twi

203 In this dose-escalation, phase 1 study we recruited patients from sev

204 The open-label, parallel-cohort, dose-escalation, phase I CheckMate 016 study evaluated the ef

205 nter, placebo-controlled, single-blind, dose-escalation pilot study, 18 subjects with perennial aller

206 iting toxic effects occurred during the dose-escalation portion of the study.

207 d6-NSmut) encoding HCV NS proteins in a dose escalation, prime-boost regimen, with and without concom

208 ced and adenosine was given following a dose-escalation protocol until atrioventricular block was ach

209 studied, nor has the effect of treatment de-escalation rather than outright cessation.

210 Real-time scoring of escalation referrals was feasible and indicated that doc

211 (doses reached after following a fixed dose-escalation regimen) or once-daily insulin glargine (star

212 3 was conducted using direct observation of escalation scenarios on surgical wards in 2 hospitals.

213 r 20 mg (escalated to 20 mg according to the escalation schedule).

214 After adjustments to the dose-escalation schedule, clinical tumor lysis syndrome did n

215 We applied a two-stage dose-escalation scheme (single patient and traditional 3+3 de

216 The phase 1 portion used a 3 + 3 dose-escalation scheme to determine the maximum tolerated dos

217 Further dose escalation should be conducted with care, as the highest

218 exhibited reactions during 5-6 weeks of dose escalation single PN and TN challenges.

219 ndard escalation; n = 71), 40-mg 8-week dose escalation (slow escalation; n = 70), 40-mg 2-week dose

220 for the first cohort in the traditional dose-escalation stage was the same as that used in the last c

221 The traditional 3+3 dose-escalation stage was triggered if toxic effects attribut

222 n the last cohort of the single-patient dose-escalation stage.

223 (n = 70), 20 mg (n = 70), 40-mg 4-week dose escalation (standard escalation; n = 71), 40-mg 8-week d

224 Compound 1 was tested in dose escalation studies in rats and dogs and was found to ind

225 Long term dose escalation studies showed that miR-30c mimic caused sust

226 In dose escalations studies in diabetic minipigs, a higher thera

227 This phase 1b, open-label, dose-escalation study assessed the safety, efficacy, and phar

228 Phase 1, open-label, uncontrolled, dose-escalation study at 5 US retinal clinics between Novembe

229 In this open-label phase 1 dose-escalation study conducted at Baylor College of Medicine

230 After an open-label dose-escalation study in a pilot safety cohort, we did a doub

231 zed, placebo-controlled, double-blinded dose-escalation study in an HIV-negative adult South African

232 We conducted a phase I dose escalation study in which 9 patients with relapsed/refra

233 Importantly, the mass-escalation study indicates that an optimized antagonist

234 d efficacy have been shown in a phase 1 dose-escalation study involving a unilateral subretinal injec

235 The dose-escalation study is the first part of a two-part study w

236 clinical activity observed in a phase I dose-escalation study of concurrent therapy with nivolumab (N

237 safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients wit

238 We conducted a phase 1 dose-escalation study of daily oral venetoclax in patients wi

239 eukemia relapse, we initiated a phase 1 dose-escalation study of membrane-bound interleukin 21 (mbIL2

240 open-label, multisite, within-subject, dose-escalation study of oral leniolisib to assess safety, ph

241 This was a single institution dose-escalation study of pralatrexate plus romidepsin designe

242 This first-in-man dose-escalation study provides evidence of safety of intra-ar

243 A phase 1b, open-label, single-dose escalation study was conducted to evaluate safety, toler

244 This phase 1b, open-label, multicentre, dose-escalation study was done at six hospitals (one in Austr

245 A phase 1 dose-escalation study was initiated to examine the safety and

246 er suboptimal conditions, an antigen dose de-escalation study was performed in the presence of either

247 We conducted a phase I dose-escalation study with (89)Zr-desferrioxamine-IAB2M ((89)

248 label, single-arm, first-in-man phase 1 dose-escalation study, eligible patients had advanced ALK-pos

249 INTERPRETATION: In this phase 1, dose-escalation study, lorlatinib showed both systemic and in

250 Patients and Methods Using a 3 + 3 + 3 dose-escalation study, nine chemotherapy-naive patients (five

251 In this phase 1 dose-escalation study, we enrolled 4 healthy volunteers and 2

252 id tumors were treated with AM0010 in a dose-escalation study, which was followed by a renal cell can

253 ed in a masked, multicenter, phase 1 dose de-escalation study.

254 has been shown to be safe in a phase 1 dose-escalation study.

255 response and environmental influences on de-escalation success and failure.

256 , patient and environmental influences on de-escalation success or failure.

257 y but strongly predictive of early treatment escalation, suggesting that broadening antibiotic treatm

258 De-escalation techniques are recommended to manage violence

259 To obtain staff descriptions of de-escalation techniques currently used in mental health se

260 o the implementation and effectiveness of de-escalation techniques in practice are not well understoo

261 y conceptualised by staff as a feature of de-escalation techniques, yet, there was evidence of a link

262 of restrictive practices through enhanced de-escalation techniques.

263 groups had higher rates of antimicrobial de-escalation than the control group (34%), with de-escalat

264 ea) improved during the first 3 months of de-escalation, though not thereafter.

265 Dose escalation to 22.5 mg/week was allowed after 8 weeks of

266 herin-mediated cell adhesion, followed by an escalation to forces higher than 43 pN (nominal value).

267 ed after 4 months of omalizumab/placebo with escalation to maintenance over 22 to 40 weeks, followed

268 Venetoclax was dosed daily using a stepwise escalation to target doses (200-600 mg) and then monthly

269 n was well tolerated, which allowed for dose escalation to the highest planned dose level (topotecan

270 effects occurred in 56% of the patients; re-escalation to the starting dose was feasible in 32% of t

271 Lenalidomide dose escalation (to 5 mg or 10 mg per day) was permitted if t

272 is open-label, single-centre, phase 1a, dose-escalation trial (part of the JAVELIN Solid Tumor trial)

273 tested in a phase 1/2a first-in-human dosage escalation trial for patients with relapsed CD37+ indole

274 rrently in a phase 1/2a first-in-humans dose escalation trial for patients with relapsed CD37-positiv

275 A recent randomized radiation dose-escalation trial in unresectable stage III non-small-cel

276 We performed an open-label phase 1/2A dose-escalation trial of 3 subcutaneous doses of recombinant

277 phase 1b, open-label and double-blind, dose-escalation trial of ChAd3-EBO-Z in Mali, we recruited ad

278 ised, double-blind, placebo-controlled, dose-escalation trial of intravenous multipotent adult progen

279 -blind, randomised, placebo-controlled, dose-escalation trial was done at a single research unit base

280 Phase 1 dose escalation trial.

281 ients received CAR-BCMA T cells in this dose-escalation trial.

282 mphoma were eligible for this phase 1b, dose-escalation trial.

283 se 1, placebo-controlled, double-blind, dose-escalation trials of an rVSV-based vaccine candidate exp

284 ted radiation therapy, immunotherapy, and de-escalation trials, might allow for improved treatment to

285 our institution on several prospective dose-escalation trials.

286 Dose escalation used a 3+3 design from a starting dose level

287 dose were estimated, and the effect of mass escalation was analyzed.

288 This escalation was based on meeting treatment failure criter

289 A cell dose escalation was conducted, starting at 10(7) total cells

290 Non-escalation was highest in RHP asymmetric dyads of the se

291 De-escalation was possible for patients receiving weekly ad

292 Treatment escalation was required by nine (7%) patients in the mes

293 Antegrade wire escalation was the preferred primary strategy in 77%, fo

294 Proposed theories or models of de-escalation were assessed against quality criteria.

295 Five theories of de-escalation were proposed; while each was adequate in som

296 ormation about the specific attributes of de-escalation were subject to thematic analysis.

297 CALM is the first study to show that timely escalation with an anti-tumour necrosis factor therapy o

298 ctory CLL or NHL underwent intrapatient dose escalation with each agent.

299 cations of SIT require a long period of dose escalation with soluble antigen (Ag) and carry a signifi

300 e factor against alcohol consumption and its escalation, working through Pax6/Eomes.